These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 32663575)

  • 1. Tackling the cytokine storm in COVID-19, challenges and hopes.
    Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
    Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges.
    Hajivalili M; Hosseini M; Haji-Fatahaliha M
    Life Sci; 2020 Sep; 257():118058. PubMed ID: 32653518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
    Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
    Front Immunol; 2020; 11():1708. PubMed ID: 32754163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
    Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
    Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
    Front Immunol; 2020; 11():1648. PubMed ID: 32754159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
    Castelli V; Cimini A; Ferri C
    Front Immunol; 2020; 11():2132. PubMed ID: 32983172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
    Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
    Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
    Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
    Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
    Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
    Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
    Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
    Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2: a storm is raging.
    Pedersen SF; Ho YC
    J Clin Invest; 2020 May; 130(5):2202-2205. PubMed ID: 32217834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.